Core Viewpoint - The article discusses the ongoing legal actions and compensation claims against Yitong Century (宜通世纪) due to false statements that have led to investor losses, highlighting the potential for further claims by affected investors [1][3][4]. Group 1: Legal Proceedings - Yitong Century has been ordered by the Guangzhou Intermediate People's Court to compensate 109 investors a total of 2,729,003.27 yuan for investment losses, with a deadline of fifteen days from the judgment date for payment [4]. - The law firm Shanghai Jiucheng, represented by lawyer Xu Feng, is actively pursuing compensation claims for investors who purchased Yitong Century shares between April 3, 2018, and November 4, 2022, and either sold or continued to hold the shares after November 4, 2022 [3][5]. Group 2: Regulatory Actions - On June 21, 2023, Yitong Century received an administrative penalty decision from the China Securities Regulatory Commission (CSRC) due to violations related to financial misstatements during a major asset restructuring in October 2016 [2][4]. - The restructuring involved the acquisition of 100% of Shenzhen Beitai Health Measurement Analysis Technology Co., Ltd. for a total consideration of 1 billion yuan, which included issuing 21.7899 million shares and cash payment of 440 million yuan [2][4]. Group 3: Financial Misconduct - From May 1 to December 31, 2017, Beitai Health engaged in financial fraud, inflating revenue by 97.3439 million yuan, costs by 52.6099 million yuan, and total profit by 40.8386 million yuan, which represented 3.7%, 9.75%, and 15.67% of Yitong Century's reported figures, respectively [5].

Core Viewpoint - The article discusses the misleading statements made by Aolian Electronics regarding the achievements of Xu Mingjun in the perovskite industry, which have led to legal actions and investor claims for compensation [2][4][5]. Group 1: Misleading Statements - Aolian Electronics disclosed that Xu Mingjun's achievements in the perovskite field contained misleading statements, as he did not play a leading or key role in the 12 projects mentioned [2][3]. - The term "completion" used in the announcement only indicates Xu's participation in the projects, while "guidance" refers to suggestions he made, lacking significant technical or process contributions [3][4]. Group 2: Impact on Stock Performance - Following the announcement of the cooperation agreement on December 12, 2022, Aolian Electronics' stock price rose by 20.01%, while the ChiNext index fell by 0.79%, indicating a deviation of 20.80 percentage points [4][7]. - After the clarification statement from Huaneng Qingneng Institute on February 21, 2023, Aolian Electronics' stock price dropped by 29.92% over the next two days, while the ChiNext index only fell by 1.16%, showing a deviation of 28.76 percentage points [4][7]. Group 3: Legal Actions and Investor Claims - The Shanghai Jiucheng Law Firm, led by lawyer Xu Feng, is actively pursuing claims for investors who purchased Aolian Electronics' stock between December 12, 2022, and February 21, 2023, and are still holding or sold their shares after the clarification [5][7].

Core Viewpoint - The article discusses the legal actions taken against Ningke Biological (600165) for false statements in its financial reporting, highlighting the ongoing investor compensation efforts and the company's regulatory violations. Group 1: Legal Actions and Compensation - The Shanghai Jiucheng Law Firm, represented by lawyer Xu Feng, has submitted a new case for investor compensation related to Ningke Biological's false statements, with some investors already receiving compensation [1][5] - The law firm continues to accept claims from other investors affected by the company's actions [1][5] Group 2: Regulatory Violations - Ningke Biological's 2022 annual report contained false records, inflating revenue by 76.5941 million yuan and profit by 77.222 million yuan, which accounted for 11.25% and 46.59% of the total revenue and profit, respectively [5] - The company failed to timely disclose significant events, including major debts and the freezing of key bank accounts [2][6] - Additionally, the company did not disclose that a subsidiary's main business had come to a halt [3][5]

受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 上海久诚律师事务所股票索赔律师许峰提示，江苏吴中（600200）终止上市暨摘牌日为2025年12月31 日，江苏吴中虽已退市，但虚假陈述引发的投资者索赔案还在持续推进，投资者如果因此受损，需要尽 快索赔。（许峰律师专栏） （本文由上海久诚律师事务所主任许峰律师供稿，不代表新浪财经立场。许峰律师，2008年起律师执 业，执业服务范围涉及虚假陈述、内幕交易、操纵市场等证券欺诈领域索赔代理。十几年来已代理近两 百只股票的投资者胜诉或调解获赔，同期还在代理诉讼时效内近三百只股票的索赔案件，部分也已有胜 诉以及调解获赔先例。投资者不获赔没有任何费用。执业证号：13101200810965495） 责任编辑：韦子蓉 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 一、未如实披露实际控制人，2018年至2023年年度报告存在虚假记载 2018年2月，江苏 ...

许峰律师代理的长药控股投资者索赔案已向武汉市中级人民法院提交立案，目前正在等待法院的下一步 安排，律师团队同步还在继续推进后续案件的立案工作，还在继续接受其他投资者的索赔委托，长药控 股投资者索赔案已有投资者胜诉先例。 2025年12月26日，长药控股公告收到证监会下发的《行政处罚事先告知书》，根据《告知书》认定的事 实，公司2021年、2022年、2023年年度报告存在虚假记载，2021年至2023年年度报告分别虚增营业收入 21，532.38万元、28，373.66万元、23，363.46万元，占当期对外披露营业收入的9.12%、17.57%、 19.51%；虚增利润总额5，640.14万元、6，337.52万元、4，370.50万元，占当期对外披露利润总额绝对 值的35.62%、88.23%、6.42%。同时，由于2022年对长江伟创中药城交易中心工程项目未合理确认损 失，导致公司2022年年度报告虚增利润总额455.24万元，占当期对外披露利润总额的6.34%。公司可能 触及《深圳证券交易所创业板股票上市规则》第10.5.2条第（六）项的"根据中国证监会行政处罚决定载 明的事实，公司披露的年度报告财务 ...

Core Viewpoint - The article discusses ongoing legal actions for investor compensation against Nanjing Panda Electronics due to significant discrepancies between the company's profit forecasts and actual financial results, indicating potential false statements made by the company [1][2]. Group 1: Company Financial Discrepancies - Nanjing Panda announced an estimated net profit for 2023 of approximately 16.19 million to 24.29 million yuan, with a net profit excluding non-recurring gains and losses expected to be between -3.27 million and 4.82 million yuan [1]. - The actual net profit reported on March 29, 2024, was a loss of 237.86 million yuan, and the net profit excluding non-recurring gains and losses was a loss of 257.01 million yuan, showing a significant deviation from the earlier forecast [1]. Group 2: Legal Actions and Investor Rights - Investors who purchased Nanjing Panda stock between January 31, 2024, and March 29, 2024, and sold or continued to hold the stock after March 29, 2024, are eligible to initiate compensation claims [2]. - The law firm involved has a history of successfully representing investors in similar cases, having handled nearly 200 cases with favorable outcomes and currently managing around 300 ongoing claims [2].

综上，普利制药2021年多计营业收入514，604，184.72元，占当年披露营业收入的34.11%，对应营业成 本206，585，749.23元，多计利润总额308，018，435.49元，占当年披露利润总额的65.88%；2022年多 计营业收入515，899，077.56元，占当年披露营业收入的28.56%，对应营业成本128，481，820.04元， 多计利润总额387，417，257.52元，占当年披露利润总额的88.27%。普利制药披露的2021年年报、2022 年年报存在虚假记载。 专门从事投资者索赔法律事务的上海久诚律师事务所主任许峰律师认为，在2022年4月26日到2024年4月 17日之间买入普利制药股票，并且在2024年4月17日后卖出或继续持有股票的投资者，目前还可发起索 赔。（普利制药维权入口） （本文由上海久诚律师事务所主任许峰律师供稿，不代表新浪财经立场。许峰律师，2008年起律师执 业，执业服务范围涉及虚假陈述、内幕交易、操纵市场等证券欺诈领域索赔代理。十几年来已代理近两 百只股票的投资者胜诉或调解获赔，同期还在代理诉讼时效内近三百只股票的索赔案件，部分也已有胜 诉以及调解获赔 ...

受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 2025年12月18日，上海久诚律师事务所股票索赔律师许峰代理的宁科生物（600165）虚假陈述投资者索 赔案出现重要进展，部分投资者已经收到赔偿款。同日，律师再代理投资者向法院提交一次立案。（许 峰律师专栏） 许峰律师代理的宁科生物投资者索赔案收到法院送达的判决书，投资者获得胜诉。律师团队还在继续推 进后续案件的立案工作，还在继续接受其他投资者的索赔委托。 2024年4月4日，宁科生物公告公司及虞建明收到证监会宁夏监管局下发的《行政处罚决定书》，经查 明，宁科生物违法事实如下： （一）2022年年度报告存在虚假记载 2022年，宁科生物通过其控股子公司宁夏中科生物新材料有限公司（以下简称中科新材），虚增2022年 营业收入7，659.41万元，虚增利润总额7，722.20万元，分别占当期营业收入和利润总额的11.25%、 46.59%，导致宁科生物2022年年度报告存在虚假记载。 （二）未按规定 ...

Core Viewpoint - The article discusses the legal actions taken against Zhiyun Co., Ltd. (智云股份) due to false statements leading to investor claims, with some investors already winning their cases [2][3]. Group 1: Legal Issues - Zhiyun Co., Ltd. received an administrative penalty from the China Securities Regulatory Commission (CSRC) on March 17, 2025, for illegal activities related to the acquisition of Shenzhen Jiutian Zhongchuang Automation Equipment Co., Ltd. [2][5] - In 2022, Jiutian Zhongchuang falsely recognized sales revenue of 59.7345 million yuan and profit of 24.1123 million yuan, which accounted for 13.27% and 7.09% of Zhiyun's total reported revenue and profit, respectively [2][6]. Group 2: Investor Claims - Investors who purchased Zhiyun shares between April 28, 2023, and April 13, 2024, and sold or held the shares after April 13, 2024, are eligible to file claims for compensation [3][7]. - The law firm Shanghai Jiu Cheng has been actively pursuing further claims and accepting new investor cases related to the false statements [4].

Core Viewpoint - Investors in Dingxin Communications (603421) are encouraged to pursue claims due to false statements made by the company, with successful precedents already established in court [1][2]. Group 1: Legal Proceedings and Investor Claims - Dingxin Communications has faced lawsuits from investors due to false statements, with some investors already winning their cases [1][2]. - The law firm Shanghai Jiucheng, led by lawyer Xu Feng, is actively accepting claims from affected investors and has a history of successful litigation in similar cases [2][5]. - Investors who purchased Dingxin Communications stock between March 1, 2024, and March 30, 2024, and sold or held their shares after March 30, 2024, are eligible to file claims [5]. Group 2: Regulatory Violations - On May 9, 2024, Dingxin Communications received an administrative penalty from the Qingdao Securities Regulatory Bureau for failing to disclose significant changes in external operating conditions [3][4]. - The company was aware as of February 27, 2024, that the State Grid had initiated a bidding "circuit breaker" mechanism affecting all procurement categories, which significantly impacted the company's revenue [4]. - The failure to disclose this information in a timely manner constitutes a violation of Article 80 of the Securities Law, which mandates prompt disclosure of major events [4].